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ABSTRACT: The study reports the use of extended 
gate field-effect transistors (FET) for the label-free 
and sensitive detection of prostate cancer (PCa) bi-
omarkers in human plasma. The approach integrates 
for the first time hybrid synthetic receptors compris-
ing of highly selective aptamer-lined pockets (apta-
MIP) with FETs for sensitive detection of prostate 
specific antigen (PSA) at clinically relevant concen-
trations. The hybrid synthetic receptors were con-
structed by immobilising an aptamer-PSA complex 
on gold and subjecting it to 13 cycles of dopamine 
electropolymerisation. The polymerisation resulted in 
the creation of highly selective polymeric cavities that 
retained the ability to recognize PSA post removal of 
the protein. The hybrid synthetic receptors were sub-
sequently used in an extended gate FET setup for 
electrochemical detection of PSA. The sensor was 
reported to have a limit of detection of 0.1 pg/ml with 
a linear detection range from 0.1 pg/ml to 1 ng/ml 
PSA. Detection of 1-10 pg/mL PSA was also achieved 
in diluted human plasma. The present apta-MIP sen-
sor developed in conjunction with FET devices 
demonstrates the potential for clinical application of 
synthetic hybrid receptors for the detection of clini-
cally relevant biomarkers in complex samples. 
Field-effect devices are attractive transduction plat-
forms for label-free sensing of bio-recognition events1,2. 
A typical metal–oxide–semiconductor field-effect tran-
sistor (MOSFET) consists of four terminals, namely the 
gate, drain, source and body. In the majority of applica-
tions, including biosensing, the source and body termi-
nals of the device are connected internally, making it a 
three terminal device2. When potential difference is ap-
plied at the gate terminal, a conducting channel is creat-
ed between the drain and source terminals of the device. 
The electrical charges in the channel can then be made 
to flow from the source to the drain by applying a volt-
age between them, provided the potential at the gate 
terminal is above the threshold potential of the device. 
For the purpose of biological and chemical sensing, the 
gate of the transistor can be extended out of the device 
to facilitate bio-functionalisation of the gate surface3. 
The interaction of these extended gates with the analyte 
of interest changes the effective surface potential of the 
gate terminal, which in turn modulates the channel con-
ductivity and changes the current between source and 
drain terminal. The use of extended gates leads to an 
improved environmental stability of MOSFETs, which 
allows sensitive detection of biomolecules and provides 
flexibility in bio-functionalisation of the device. One 
significant advantage of MOSFETs is their suitability for 
use in miniaturized measurement systems, thereby al-
lowing ease of integration with electronic readouts. In 
this regard, the MOSFET system is applicable to a range 
of point-of-need applications including those within 
healthcare and environmental monitoring industries4. 
Extended gate FETs have been widely used for DNA 
hybridisation5, aptamer-protein interaction6, enzymatic 
activity detection7 and small molecule detection using 
molecularly imprinted polymers (MIPs)8,9. However, the 
application of FET devices and in particular MOSFETs 
for the sensing of proteins using MIPs is yet to be ex-
plored. 
The process of molecular imprinting involves synthe-
sising synthetic receptors by polymerising functional 
monomers around a template to form polymer cavities 
that display steric and chemical selectivity for the tem-
plate and related molecular species10. Molecular imprint-
ing offers various advantages over biological receptors 
in terms of stability, robustness and ease of engineering 
onto various sensing platforms. The field of molecular 
imprinting has continuously strived to become a viable 
alternative to antibodies for detection of proteins; how-
ever, conventional imprinting of proteins has proven 
challenging as a result of their large size, complexity and 
 dynamic nature11. Epitope imprinting, which uses an 
epitope presented on the protein surface as the template 
for imprinting in order to capture the whole protein, has 
been used as an alternative to whole protein imprint-
ing12. However, the absence of established crystal struc-
tures and known epitopes for most proteins are key bar-
riers for adopting the technique as an alternative to pro-
tein recognition and sensing. Hybrid imprinting is an 
emerging subset of molecular imprinting, which incor-
porates (bio)receptors with established affinity towards 
the template into the polymer cavities to generate hybrid 
synthetic receptors which display superior binding char-
acteristics13. Hybrid receptors of this type have been 
generated using DNA aptamers14, small molecules15 and 
antibodies16 for the sensitive detection of proteins. We 
have previously reported a sensitive capacitive sensor 
for prostate specific antigen (PSA) using hybrid recep-
tors13. This study extends our previous findings by re-
porting a highly sensitive DNA aptamer-based hybrid 
MOSFET sensor for the detection of PSA. MOSFETs 
are ubiquitous in all electronic device, can be easily in-
tegrated into simple electronics and devices and have 
been shown to provide better sensitivity than capacitive 
sensors3. Although the limitations of PSA as a biomarker 
for PCa have been well noted in the literature, it remains 
the most commonly used biomarker for screening, moni-
toring the effectiveness of treatment and assessing like-
lihood of remission post treatment.17 Furthermore, the 
commercial availability of both PSA protein standards 
and a high affinity anti-PSA aptamer, make it a good 
target for this first proof-of-concept study. 
 
Figure 1:	 (a) Modification of gold electrodes with anti-PSA 
aptamer followed by electropolymerisation of polydopa-
mine to imprint the aptamer and PSA. (b) Removal of pro-
tein to expose pockets for rebinding. (c) Use of apta-MIP 
modified electrodes in an extended gate MOSFET setup for 
rebinding of PSA. 
 
 
EXPERIMENTAL SECTION 
Reagents: Thiol terminated anti-PSA DNA aptamer 
(5’-HS-(CH2)6-TTT TTA ATT AAA GCT CGC CAT 
CAA ATA GCT TT-3’) was obtained from Sigma-
Aldrich, UK. PSA was obtained from Merck Chemicals 
Ltd, UK. Human glandular Kallikrein 2 (hK2) was ob-
tained from RnD Systems, UK. All other reagents were 
of analytical grade and obtained from Sigma-Aldrich, 
UK. All aqueous solutions were prepared using 18.2 MΩ 
cm ultra-pure water from a Milli-Q system with a Py-
rogard filter (Millipore, MA, USA).  
Apta-MIP preparation: Thiolated aptamer was acti-
vated at 95° C for 10 min before being gradually cooled 
to room temperature for 30 min. Thereafter, 1 µM ap-
tamer in TBST buffer (10 mM Tris-HCl, 10 mM KCl, 10 
mM MgCl2, 0.05% Tween 20, pH 7.4)) was incubated 
with 1 µg/ml of PSA for 1 hour at 37°C. Clean array of 
gold electrodes (180nm) were then exposed to the result-
ing aptamer-PSA complex solution for one hour before 
being rinsed carefully with ultra pure water. The elec-
trodes were subsequently incubated with 1 µg/ml PSA 
for an additional 30 min before rinsing with ultrapure 
water and drying under nitrogen. The molecular imprint-
ing step was performed by electropolymerising dopa-
mine on to the aptamer-PSA modified electrode. Briefly, 
10 mM PBS buffer (pH 7.4) containing 5 mM dopamine 
was degassed with nitrogen (10 min) and then electro-
polymerised using cyclic voltammetry (13 cycles, -0.5 V 
to 0.5 V vs Ag/AgCl, scan rate of 20 mV/s performed on 
µAUTOLAB III / FRA2 potentiostat (Metrohm Autolab, 
The Netherlands). Electrodes were rinsed with water and 
washed (with stirring) overnight in washing solution 
(5% v/v acetic acid and 5% w/v sodium dodecyl sul-
phate (SDS) in water) to remove the PSA template. Elec-
trodes were then rinsed with water to remove residual 
acid and detergent before being allowed to stabilise in 
measurement buffer (10 mM PBS (pH 7.4). A non-
imprinted ‘control’ electrode (apta-NIP) was prepared in 
the same way but in the absence of PSA. 
MOSFET measurements: MOSFET measurement 
were performed on an extended-gate FET sensor con-
sisted of an array of gold electrodes, where MIPs were 
immobilised and the FET structure, which transduced 
the binding events on the gold electrode into electrical 
signals. Arrays of gold (180 nm) electrodes were grown 
on a glass substrate, using thermal evaporation. The ex-
tended gate was fabricated by connecting the Au elec-
trodes, fixed in a reaction cell, to the gate of a n-
MOSFET via a metal wire. Detailed information on the 
specifications of the CMOS chip can be found in litera-
ture.18 To operate the transistor for the measurements, a 
voltage of 50 mV was applied across the drain to source 
and gate-source voltage (Vgs) was swept from 0 to 4 V.  
These settings limited the current to less than 75 µA to 
avoid any changes in Vgs due to heating. 
 Aptamer only evaluation: Experiments with PSA ap-
tamer alone were performed using the same gold evapo-
rated electrodes following the protocol reported by pre-
viously.19 Briefly, electrodes were exposed to thiolated 
DNA aptamer/6-mercapto- 1-hexanol (MCH, Sigma, 
UK) immobilization solution for 16 hrs in a humidity 
chamber. An optimized (1:100) DNA aptamer to total 
thiol was used to fabricate the biosensor. A high concen-
tration of MCH was prepared in ethanol, which was di-
luted to working concentration in 10 mM PBS (pH 7.4). 
Prior to addition of MCH, DNA aptamers were heated to 
95 °C for 10 min followed by gradual cooling over 30 
min to room temperature. After immobilization, elec-
trodes were rinsed with excess MilliQ water to remove 
unattached thiols. In order to ensure complete thiol cov-
erage of the gold surface, the electrodes were thereafter 
backfilled with 1 mM MCH for 1 h. Electrodes were 
then rinsed with MilliQ water and placed in the 10 mM 
PBS (pH 7.4) for stabilization. 
Sensor Performance: To evaluate sensor perfor-
mance, electrodes were exposed to 100 µl of a range of 
PSA concentrations (10-2 – 108 pg/ml) in 10 mM PBS 
buffer pH 7.4. for 30 minutes. Post incubation with PSA 
the electrodes were washed thoroughly with PBS. For 
plasma experiments, blood obtained from a healthy fe-
male volunteer was spun down (3200 rpm, 20 minutes) 
to remove the red blood cells. The resultant plasma was 
diluted 1000 times in a PBS buffer of pH 7.4 and then 
spiked with varying concentrations of PSA (1, 5, 10 
pg/ml PSA). For detection of binding, a voltage of 50 
mV was applied between the drain and source (Vd or 
Vds) to operate the transistor and the gate-source voltage 
(Vgs) was swept from 0.0 to 5.0 V. All electrical meas-
urements were conducted using an Agilent B1500A sem-
iconductor device analyser. Measurements for all exper-
iments were recorded for 4 different devices. 
RESULTS AND DISCUSSION 
Fig. 2(a) shows the response of the device upon incu-
bation with increasing concentrations of PSA in PBS. 
Fig. 2(b) shows the transfer characteristics of the device 
upon binding to different concentrations of PSA. An 
initial change of 30 mV was obtained for lower concen-
trations (1-10 fg/mL) following which a linear response 
was obtained from 0.1 to 10 pg/mL of PSA. Above 100 
pg/mL, the voltage shifts remain almost constant, sug-
gesting saturation of the binding sites. A maximum volt-
age change of 158 ± 43 mV was observed at a concen-
tration of 1 µg/mL of PSA. The apta-NIP experiments 
revealed voltage shifts of 20 times lower (8 ± 3 mV, Fig. 
2) than that observed in the apta-MIP for the same con-
centrations of PSA. The initial change of 30 mV at con-
centrations between 1 and 10 fg/mL could be attributed 
to small amounts of weak binding of PSA to the aptamer 
causing a conformational change and hence changes in 
the distribution of charges in the bilayer.  Beyond 0.1 
pg/mL a case can be made for specific interaction of the 
protein with the apta-MIP surface, increasing the shift in 
voltage as a result of the aptamer charges being screened 
and the protein binding to the polymeric cavity dominat-
ing the charge behaviour at the surface. The FET sensor 
can detect local net-charges of PSA because of the 
smaller sensing depth (the Debye length) compared to 
the size of protein. It is hypothesised that upon rebinding 
of PSA (with a certain net charge) to the apta-MIP, there 
is a change in the electrochemical double layer and in 
the charge distribution of the bilayer, which causes a 
variation in the potential drop at the gate of the 
MOSFETs. A positive shift in voltage observed upon 
binding of PSA to apta-MIP corresponds to an increase 
in negative charges on the surface of the sensor; it is 
hypothesised that this is an effect of net negative charge 
of PSA.20 The apta-MIP bio-FET device was approxi-
mately 10 times more sensitive than an impedance spec-
troscopy (EIS) sensor reported previously by our 
groups14 suggesting that the MOSFET device is a better 
platform for biosensing with apta-MIPs. In the case of 
the apta-NIPs, the absence of a polymeric cavity restricts 
much of the binding to PSA, which leads to a small 
change in voltage. It is proposed that the aptamers be-
come entrapped within the polymeric network in the 
absence of PSA and hence, post-polymerisation access 
to the aptamer-binding site is severely hindered.  
 
Figure 2:	 (a): Dose response of PSA with apta-MIP FET 
device. (b) Transfer characteristics curve of apta-MIP FET 
device binding to PSA. 
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 To understand the selectivity of the sensor, the apta-MIP 
bio-FET device was subjected to stringent controls; 
comparing the response with the protein hK2, which has 
80% homology with PSA, in a non-competitive assay. 
The response to 1 µg/mL hK2 was significantly lower 
(56 ± 14 mV) than the change observed with an equiva-
lent concentration of PSA (158mV) (Fig. 3). This sug-
gests that whilst some cross-reactivity is observed the 
system is able to distinguish between the template and 
closely related proteins. Interestingly in the previous 
study14, where binding to aptamer alone was investigat-
ed, lower cross reactivity with hK2 (18%) was observed 
when compared to the apta-MIP (28%). This suggests 
that the enhanced cross-reactivity observed with the ap-
ta-MIP arises as a result of interactions between hK2 and 
the polymer network. The aptamer itself has been de-
signed to limit cross-reactivity with structurally related 
proteins and as such targets one relatively small epitopic 
region on the PSA protein. It is not surprising therefore, 
that when we build a polymer network around the ap-
tamer-PSA complex, which introduces a second layer of 
interactions that likely occur over a much larger surface 
area of the protein than that of the aptamer, that a greater 
degree of cross-reactivity with a highly homologous 
protein is observed. When challenged with human serum 
albumin, a structurally unrelated protein, minimal re-
sponse was observed. It should also be noted that the 
concentration hK2 in clinical samples is 100 times lower 
than PSA and therefore in practice it is unlikely to inter-
fere in binding of PSA.21 
 
Figure 3: The Apta-MIP sensor demonstrated a signifi-
cantly larger response to 1 µg/mL PSA when compared to 
the Apta-NIP system. Some cross-reactivity was observed 
when the apta-MIP was challenged with 1 µg/mL hK2. 
  
It was important to compare the apta-MIP sensor with 
an aptamer only device so as to understand whether an 
improvement in recognition performance was achieved 
as a result of imprinting. On comparing an apta-MIP 
with an aptamer alone FET sensor (see curve for ap-
tamer/MCH in Fig. 4), a significantly lower sensitivity 
was observed for the aptamer only sensor. The aptamer 
only FET displayed a shift of 18 mV compared to 158 
mV shift of apta-MIP at 1 ng/mL PSA. A negative shift 
in voltage was observed at 0.1 pg/mL, which could be a 
result of non-specific binding of PSA to the MCH self-
assembled monolayer. A positive shift in voltage was 
observed upon increasing the concentration, however the 
response was much lower than for the apta-MIP sensor, 
suggesting an improvement in the sensitivity of the hy-
brid MIP system. A previous study has showed that 
varying the polymer thickness influences sensor perfor-
mance, which supports the hypothesis that the polymer 
plays a role in PSA recognition.14 
 
Figure 4: Comparison of apta-MIP and aptamer/MCH 
response to PSA. The aptamer only system displays 
poorer sensitivity than the apta-MIP system. 
 
The sensor was further tested in human plasma to 
evaluate its potential use in clinical applications. Human 
plasma from a healthy female volunteer was used to en-
sure no interference from any background PSA levels. 
Spiking the plasma with PSA allowed for the measure-
ment of known levels of PSA in the plasma (low back-
ground PSA) whilst maintaining the ratio of PSA/plasma 
proteins. The high sensitivity of this device for PSA 
demonstrated in-vitro means that clinically relevant lev-
els of PSA (4-10 ng/mL22) can be readily detected even 
following a 1/1000 dilution of plasma. When 1/1000 
diluted female plasma (no PSA added) was applied to 
the sensor little change in response was observed (Fig. 
5). This suggests good resistance of the apta-MIP sur-
face to plasma protein fouling. Upon incubation of the 
sensor with plasma containing 1-10 pg/mL PSA (spiked 
after dilution of plasma) a linear response was observed. 
Although the sensitivity was lower than observed with 
simple buffer PSA solutions, the results are highly en-
couraging given the ability to directly detect clinically 
relevant concentrations. The loss in sensitivity is likely 
explained by protein-protein interactions, which has also 
been observed in aptamer ELISA assays23. The free PSA 
used in the current assay is derived from seminal fluid, 
which is known to interact with complement proteins, 
anti-chymotrypsin and albumin present in plasma, which 
could prevent it from interacting with the apta-MIP 
hence, lowering the sensitivity of the sensor. Free PSA 
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 present in patient blood however is internally cleaved, 
thereby avoiding interaction with anti-chymotrypsin22 
and so an improvement in system sensitivity maybe ob-
served with real clinical samples. 
 
Figure 5:	 Apta-MIP response in 1000X diluted plasma 
spiked with PSA. 
 
CONCLUSIONS 
In conclusion, the work presents for the first time the 
use of MOSFET devices for sensing a disease related 
protein using a hybrid synthetic receptor. A sensitive 
MOSFET apta-MIP device has been developed that has 
improved sensitivity when compared with an equivalent 
aptamer only MOSFET sensor and a previously reported 
impedimetric apta-MIP device. In addition, negligible 
response of the apta-MIP surface to diluted plasma and 
the systems intrinsic high sensitivity meant that PSA 
could be detected in 1/1000 diluted plasma over a clini-
cally relevant concentration range. The combination of 
hybrid MIP receptors with MOSFET devices could help 
develop the next generation of robust hybrid biosensors 
that could be translated to other clinical markers.  
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GRAPHICAL ABSTRACT:  
 
